Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of the Safety and Immunogenicity of RiVax With Alum in Healthy Adults

Next Previous
Trial Profile

Phase 1 Study of the Safety and Immunogenicity of RiVax With Alum in Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ricin vaccine (Primary) ; Alum
  • Indications Ricin poisoning
  • Focus Adverse reactions

Most Recent Events

  • 19 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 30 Aug 2012 According to a Soligenix media release, this trial was supported by a combination of grants including a $940,000 grant from the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA).
  • 28 Aug 2012 Planned End Date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top